Evolocumab
- Generic Name
- Evolocumab
- Brand Names
- Repatha
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1256937-27-5
- Unique Ingredient Identifier
- LKC0U3A8NJ
- Background
Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies....
- Indication
Evolocumab is indicated in adult patients with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization. It is also indicated as an adjunct to diet, alone or in combination with other hypolipidemic treatments, in adults with primary hyperlipidemia (and in pediatric patients ≥10 years old with hete...
- Associated Conditions
- Coronary Revascularization, Myocardial Infarction, Stroke, Increases in serum total low-density lipoprotein (LDL)
- Associated Therapies
- -
CARotid plaqUe StabilizatiOn and Regression With Evolocumab.
- Conditions
- Interventions
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Azienda Ospedaliera Ordine Mauriziano di Torino
- Target Recruit Count
- 130
- Registration Number
- NCT04730973
- Locations
- 🇮🇹
Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Piedmont, Italy
Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04719221
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Hamid Al-Essa Organ Transplant Center
- Target Recruit Count
- 200
- Registration Number
- NCT04665830
- Locations
- 🇰🇼
OTC, MOH , Kuwait, Kuwait, Kuwait
Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Policlinico Casilino ASL RMB
- Target Recruit Count
- 50
- Registration Number
- NCT04659525
- Locations
- 🇮🇹
Policlinico Casilino, Rome, Italy
Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 70
- Registration Number
- NCT04613167
- Locations
- 🇸🇮
University Medical Centre Ljubljana-Department of Vascular diseases and dept. of Cardiology, Ljubljana, Slovenia
Lipid Management in Renal Transplant Recipients Using Evolocumab.
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04608474
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study of Evolocumab on Carotid Artery Atherosclerotic Plaque Morphology Prior to Carotid EndArterectomy
- Conditions
- Interventions
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2022-05-02
- Target Recruit Count
- 60
- Registration Number
- NCT04539223
- Locations
- 🇨🇦
North York Diagnostic and Cardiac Centre, North York, Ontario, Canada
🇨🇦St. Michael's Hospital, Toronto, Ontario, Canada
🇨🇦East Toronto Vascular Clinic, Toronto, Ontario, Canada
Evolocumab In Advanced Chronic Kidney Disease Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT04510844
- Locations
- 🇺🇸
NYU Langone Nephrology Associates - Long Island, Mineola, New York, United States
🇺🇸NYU Langone Health, New York, New York, United States
Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients
- Conditions
- Interventions
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Policlinico Casilino ASL RMB
- Target Recruit Count
- 50
- Registration Number
- NCT04397653
- Locations
- 🇮🇹
Policlinico Casilino, Rome, Italy
Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 25
- Registration Number
- NCT04313270
- Locations
- 🇮🇹
Matteo Di Minno, Napoli, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.